Jussi Jaakko Saukkonen, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antitubercular Agents | 20 | 2019 | 1397 | 1.290 |
Why?
|
| Tuberculosis | 13 | 2016 | 2029 | 0.910 |
Why?
|
| Latent Tuberculosis | 6 | 2019 | 224 | 0.830 |
Why?
|
| Thorax | 1 | 2023 | 557 | 0.700 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2023 | 628 | 0.620 |
Why?
|
| Pneumonia | 3 | 2023 | 2163 | 0.500 |
Why?
|
| Alcoholism | 2 | 2023 | 1981 | 0.440 |
Why?
|
| Isoniazid | 6 | 2019 | 288 | 0.410 |
Why?
|
| Rifampin | 5 | 2019 | 351 | 0.370 |
Why?
|
| Liver Function Tests | 3 | 2012 | 526 | 0.370 |
Why?
|
| Heart | 1 | 2023 | 4448 | 0.340 |
Why?
|
| Pyrazinamide | 3 | 2004 | 60 | 0.340 |
Why?
|
| Mycobacterium tuberculosis | 9 | 2016 | 1930 | 0.330 |
Why?
|
| Immunoassay | 1 | 2011 | 746 | 0.290 |
Why?
|
| Refusal to Participate | 2 | 2019 | 30 | 0.270 |
Why?
|
| Interferon-gamma | 4 | 2011 | 3163 | 0.260 |
Why?
|
| Monitoring, Physiologic | 1 | 2012 | 1796 | 0.230 |
Why?
|
| Urban Population | 2 | 2011 | 2045 | 0.220 |
Why?
|
| Phenobarbital | 1 | 2023 | 192 | 0.210 |
Why?
|
| Medication Adherence | 4 | 2017 | 2192 | 0.210 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 2339 | 0.190 |
Why?
|
| Chemokines, CC | 1 | 2002 | 286 | 0.180 |
Why?
|
| Benzodiazepines | 2 | 2023 | 1139 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2012 | 3233 | 0.180 |
Why?
|
| Tuberculosis, Pulmonary | 3 | 2015 | 843 | 0.180 |
Why?
|
| Receptors, Fibronectin | 1 | 1999 | 37 | 0.170 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 1999 | 141 | 0.160 |
Why?
|
| Directly Observed Therapy | 2 | 2017 | 139 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2013 | 4053 | 0.150 |
Why?
|
| Community-Acquired Infections | 1 | 2021 | 473 | 0.140 |
Why?
|
| Emergencies | 1 | 2023 | 1220 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 1999 | 4651 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2006 | 2597 | 0.130 |
Why?
|
| Respiratory Insufficiency | 1 | 2004 | 1241 | 0.120 |
Why?
|
| Oxazolidinones | 2 | 2012 | 98 | 0.120 |
Why?
|
| Esophageal Stenosis | 1 | 1996 | 197 | 0.120 |
Why?
|
| Integrins | 1 | 1999 | 843 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 7460 | 0.120 |
Why?
|
| Clinical Trials as Topic | 3 | 2013 | 8055 | 0.120 |
Why?
|
| Receptors, Cytokine | 1 | 2015 | 258 | 0.110 |
Why?
|
| Th1 Cells | 1 | 1999 | 1042 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2006 | 3967 | 0.110 |
Why?
|
| Patient Selection | 2 | 2019 | 4265 | 0.110 |
Why?
|
| Acetamides | 2 | 2012 | 260 | 0.110 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 2 | 2012 | 944 | 0.110 |
Why?
|
| Bronchi | 1 | 1996 | 850 | 0.100 |
Why?
|
| Cytokines | 2 | 2015 | 7453 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2007 | 4356 | 0.100 |
Why?
|
| Liver | 3 | 2006 | 7579 | 0.100 |
Why?
|
| Tuberculin Test | 1 | 2011 | 205 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 10397 | 0.080 |
Why?
|
| Cough | 1 | 2013 | 598 | 0.080 |
Why?
|
| HIV Infections | 6 | 2016 | 17589 | 0.080 |
Why?
|
| Humans | 38 | 2023 | 768887 | 0.080 |
Why?
|
| Substance-Related Disorders | 1 | 2004 | 4429 | 0.070 |
Why?
|
| Chemokine CCL4 | 3 | 2002 | 127 | 0.070 |
Why?
|
| Macrophage Inflammatory Proteins | 3 | 2002 | 122 | 0.070 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 6320 | 0.070 |
Why?
|
| Specimen Handling | 1 | 2011 | 708 | 0.070 |
Why?
|
| Patient Compliance | 2 | 2006 | 2701 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1997 | 4413 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2013 | 2663 | 0.060 |
Why?
|
| Chemokine CCL5 | 2 | 2002 | 214 | 0.060 |
Why?
|
| Stents | 1 | 1996 | 3200 | 0.060 |
Why?
|
| Bronchial Spasm | 1 | 2004 | 71 | 0.060 |
Why?
|
| Patient Preference | 1 | 2011 | 947 | 0.060 |
Why?
|
| Amphetamines | 1 | 2004 | 143 | 0.050 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2004 | 192 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 3 | 1997 | 1813 | 0.050 |
Why?
|
| Solvents | 1 | 2004 | 298 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2006 | 432 | 0.050 |
Why?
|
| Narcotics | 1 | 2004 | 334 | 0.050 |
Why?
|
| Risk Factors | 6 | 2019 | 74971 | 0.050 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2002 | 99 | 0.050 |
Why?
|
| Soybean Proteins | 1 | 2001 | 55 | 0.050 |
Why?
|
| Family Practice | 1 | 2004 | 509 | 0.050 |
Why?
|
| Congresses as Topic | 1 | 2006 | 811 | 0.050 |
Why?
|
| Pulmonary Edema | 1 | 2004 | 409 | 0.050 |
Why?
|
| Administration, Inhalation | 1 | 2004 | 1169 | 0.050 |
Why?
|
| Pneumothorax | 1 | 2004 | 393 | 0.040 |
Why?
|
| Male | 19 | 2019 | 365249 | 0.040 |
Why?
|
| HIV | 1 | 2007 | 1596 | 0.040 |
Why?
|
| Prospective Studies | 6 | 2012 | 54950 | 0.040 |
Why?
|
| Macrophages | 2 | 2007 | 5800 | 0.040 |
Why?
|
| Macrophages, Alveolar | 1 | 2002 | 415 | 0.040 |
Why?
|
| Antigens, Protozoan | 1 | 2001 | 315 | 0.040 |
Why?
|
| Integrin alpha4beta1 | 1 | 1999 | 119 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2011 | 9682 | 0.040 |
Why?
|
| Cocaine | 1 | 2004 | 960 | 0.040 |
Why?
|
| Female | 18 | 2019 | 397464 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 15471 | 0.040 |
Why?
|
| Interleukin-16 | 1 | 1998 | 34 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2001 | 556 | 0.040 |
Why?
|
| Boston | 1 | 2011 | 9375 | 0.040 |
Why?
|
| Adult | 18 | 2019 | 223818 | 0.040 |
Why?
|
| Cannabis | 1 | 2004 | 446 | 0.040 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1999 | 564 | 0.040 |
Why?
|
| Bronchoalveolar Lavage | 1 | 1997 | 131 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2023 | 81892 | 0.030 |
Why?
|
| Histamine | 1 | 1998 | 496 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2004 | 1014 | 0.030 |
Why?
|
| Bronchial Neoplasms | 1 | 1996 | 111 | 0.030 |
Why?
|
| Canada | 2 | 2016 | 2129 | 0.030 |
Why?
|
| Fibronectins | 1 | 1999 | 724 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 1998 | 761 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 878 | 0.030 |
Why?
|
| Lung | 1 | 1993 | 10097 | 0.030 |
Why?
|
| Endothelium, Vascular | 2 | 1997 | 4428 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2015 | 257 | 0.030 |
Why?
|
| Treatment Outcome | 5 | 2015 | 65485 | 0.030 |
Why?
|
| Chemokines | 1 | 1998 | 963 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 1999 | 1184 | 0.030 |
Why?
|
| Cell Adhesion | 2 | 1997 | 3102 | 0.030 |
Why?
|
| Acute Disease | 1 | 2004 | 7245 | 0.030 |
Why?
|
| Cell Count | 1 | 1997 | 1833 | 0.030 |
Why?
|
| Massachusetts | 1 | 2006 | 8888 | 0.030 |
Why?
|
| Public Health | 2 | 2016 | 2680 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2011 | 24330 | 0.030 |
Why?
|
| Toll-Like Receptor 2 | 2 | 2007 | 348 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 12093 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1999 | 1895 | 0.030 |
Why?
|
| Drosophila Proteins | 1 | 2001 | 1712 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2001 | 2820 | 0.020 |
Why?
|
| Biological Availability | 1 | 2013 | 392 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 1996 | 1836 | 0.020 |
Why?
|
| Consensus | 1 | 2021 | 3214 | 0.020 |
Why?
|
| Apoptosis | 1 | 2007 | 9528 | 0.020 |
Why?
|
| Critical Care | 1 | 2004 | 2715 | 0.020 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2007 | 587 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2001 | 3714 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1997 | 1855 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2012 | 411 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 12563 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1998 | 2614 | 0.020 |
Why?
|
| Uganda | 1 | 2015 | 1354 | 0.020 |
Why?
|
| Sputum | 1 | 2012 | 517 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 1993 | 1609 | 0.020 |
Why?
|
| Middle Aged | 8 | 2013 | 223740 | 0.020 |
Why?
|
| Young Adult | 4 | 2019 | 60110 | 0.020 |
Why?
|
| Cell Movement | 2 | 1997 | 5216 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2012 | 12469 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 3814 | 0.020 |
Why?
|
| Incidence | 1 | 2006 | 21545 | 0.020 |
Why?
|
| U937 Cells | 1 | 2007 | 260 | 0.020 |
Why?
|
| South Africa | 1 | 2012 | 1872 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 1668 | 0.020 |
Why?
|
| Recurrence | 2 | 2013 | 8512 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2012 | 965 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 1469 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2007 | 432 | 0.020 |
Why?
|
| Esophageal Neoplasms | 1 | 1996 | 1674 | 0.020 |
Why?
|
| Biliary Tract Diseases | 1 | 1967 | 159 | 0.020 |
Why?
|
| United States | 5 | 2016 | 73180 | 0.020 |
Why?
|
| Biological Specimen Banks | 1 | 2011 | 789 | 0.020 |
Why?
|
| Prognosis | 1 | 2006 | 30044 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 1967 | 414 | 0.020 |
Why?
|
| Time Factors | 2 | 2017 | 40266 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 1967 | 606 | 0.010 |
Why?
|
| Adolescent | 5 | 2019 | 89247 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 3858 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1993 | 5905 | 0.010 |
Why?
|
| Aged, 80 and over | 3 | 2013 | 59738 | 0.010 |
Why?
|
| Sex Factors | 1 | 2017 | 10641 | 0.010 |
Why?
|
| Phagocytosis | 1 | 2007 | 1530 | 0.010 |
Why?
|
| Radiography | 1 | 2013 | 6991 | 0.010 |
Why?
|
| Aged | 6 | 2013 | 171790 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2019 | 42684 | 0.010 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2001 | 153 | 0.010 |
Why?
|
| Child | 3 | 2019 | 80969 | 0.010 |
Why?
|
| Qualitative Research | 1 | 2012 | 3143 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1996 | 4064 | 0.010 |
Why?
|
| Logistic Models | 1 | 2015 | 13317 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1997 | 11684 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2006 | 2359 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2012 | 8742 | 0.010 |
Why?
|
| Asthma | 1 | 1998 | 6293 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2007 | 2492 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2007 | 2885 | 0.010 |
Why?
|
| Chemokine CCL3 | 1 | 1998 | 85 | 0.010 |
Why?
|
| Cost Savings | 1 | 2004 | 915 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 7860 | 0.010 |
Why?
|
| Bronchial Provocation Tests | 1 | 1998 | 216 | 0.010 |
Why?
|
| Age Factors | 1 | 2015 | 18454 | 0.010 |
Why?
|
| Toll-Like Receptors | 1 | 2001 | 582 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2004 | 1669 | 0.010 |
Why?
|
| Research Design | 1 | 2012 | 6213 | 0.010 |
Why?
|
| Methylamines | 1 | 1977 | 136 | 0.010 |
Why?
|
| Uremia | 1 | 1977 | 202 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2006 | 2122 | 0.010 |
Why?
|
| Breath Tests | 1 | 1977 | 300 | 0.010 |
Why?
|
| Protozoan Proteins | 1 | 2001 | 844 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1998 | 660 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 39394 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 15955 | 0.010 |
Why?
|
| Macrophage-1 Antigen | 1 | 1995 | 286 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 4862 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2001 | 2222 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2001 | 2149 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2001 | 2884 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1996 | 13593 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2004 | 5544 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1995 | 1866 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 13048 | 0.010 |
Why?
|
| Immunologic Memory | 1 | 1995 | 1378 | 0.000 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1995 | 1803 | 0.000 |
Why?
|
| Cell Line | 1 | 2001 | 15603 | 0.000 |
Why?
|
| Sulfobromophthalein | 1 | 1967 | 9 | 0.000 |
Why?
|
| Clinical Enzyme Tests | 1 | 1967 | 114 | 0.000 |
Why?
|
| Mice, Knockout | 1 | 2001 | 14485 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 2006 | 26394 | 0.000 |
Why?
|
| Genital Diseases, Female | 1 | 1967 | 192 | 0.000 |
Why?
|
| Cholecystectomy | 1 | 1967 | 409 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 2001 | 9618 | 0.000 |
Why?
|
| Infant | 1 | 2006 | 36541 | 0.000 |
Why?
|
| Muscles | 1 | 1967 | 1582 | 0.000 |
Why?
|
| Gastrectomy | 1 | 1967 | 693 | 0.000 |
Why?
|
| Extremities | 1 | 1967 | 870 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1995 | 9264 | 0.000 |
Why?
|
| Dimethylamines | 1 | 1977 | 7 | 0.000 |
Why?
|
| Chromatography, Gas | 1 | 1977 | 150 | 0.000 |
Why?
|
| Mice | 1 | 2001 | 82074 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1967 | 13020 | 0.000 |
Why?
|
| Mass Spectrometry | 1 | 1977 | 2204 | 0.000 |
Why?
|
| Animals | 1 | 2001 | 169408 | 0.000 |
Why?
|
| Renal Dialysis | 1 | 1977 | 1789 | 0.000 |
Why?
|
| Myocardial Infarction | 1 | 1967 | 11521 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1967 | 15889 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1977 | 7472 | 0.000 |
Why?
|